Research Progress Of SGLT2 Inhibitors In The Treatment Of Diabetic Kidney Disease

Background:Diabetic kidney disease(DKD)is one of the major complications of Diabetes mellitu.In developed countries,it is the most common cause of End-stage renal disease(ESRD).Sodium–glucose cotransporter 2(SGLT2)inhibitor are attracting more and more attention because of their unique mechanism characteristics,especially in the treatment of Diabetic kidney disease.Objective:Provide some references for the clinical treatment of DKD by reviewing the progress of SGLT2 inhibitors in DKD research and treatment.Methods:Screen the study of SGLT2 inhibitors in the treatment of Diabetic kidney disease from CNKI?Wangfang?PubMed.Result: A number of studies about SGLT2 inhibitors in the treatment of Diabetic kidney disease have been searched.The latest research progress of SGLT2 inhibitors in the treatment of Diabetic kidney disease was summed up by reading the literature and reviewing related resources.Conclusion:SGLT2 inhibitors are independent of insulin to strengthen the control of blood glucose,but also can reduce weight?blood pressure and uric acid,In addition,SGLT2 inhibitors can improve the role of renal hemodynamics,reduce glomerular ultrafiltration and glomerular pressureand reduce urinary protein,all the effects are expected to be effective forthe treatment of Diabetic kidney disease.At the same time,some studies have shown that long-term use of SGLT2 inhibitors also have certain risks and side effects.Therefore,for kidney protection mechanisms and potential risks of SGLT2 inhibitors,more multicenter,large sample of basic and clinical data observations are needed to provide more evidence-based medical evidence for more scientific and rational use of SGLT2 inhibitors.